TG THERAPEUTICS, INC.
TG THERAPEUTICS, INC. (TGTX): 31 pipeline candidates · 6 upcoming catalysts · ~115 mo cash runway · 51 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
114.6 months
D/E 1.62 · 5% dilution
Lead: Approved
31 candidates
6 upcoming, next in ~42d
N/A
A transparent, data-derived signal for TG THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.9B
Cash
$443.6M
Quarterly Burn
$17.9M
Runway
114.6 mo
Revenue
$204.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (31 candidates)
| Drug | Phase |
|---|---|
| allogeneic engineered gingival fibroblasts | Phase 1 |
| Azer-cel | Phase 1 |
| Azercabtagene zapreleucel | Phase 1 |
| bemarituzumab | Phase 2 |
| BRIUMVI | Approved |
| cbt-001 | Phase 3 |
| delafloxacin | Phase 1 |
| Fingolimod | Phase 2/Phase 3 |
| isis 301012 | Phase 3 |
| kimyrsa | Phase 2 |
Showing 10 of 31 candidates. Sign up for full pipeline.
Upcoming Catalysts (6)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
362
Total value held
$3.64B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 22,252,930 | $739.2M |
| vanguard capital management llc | 13,206,516 | $438.7M |
| state street corp | 8,649,766 | $287.3M |
| vanguard portfolio management llc | 8,273,979 | $274.9M |
| geode capital management, llc | 3,499,916 | $116.3M |
| clearbridge investments, llc | 3,210,930 | $106.7M |
| jane street group, llc | 3,150,869 | $104.7M |
| goldman sachs group inc | 3,077,688 | $102.2M |
| citadel advisors llc | 2,443,889 | $81.2M |
| congress asset management co | 2,168,081 | $72.0M |
Showing top 10 of 362 institutional holders of TG THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in TG THERAPEUTICS, INC.'s pipeline?
TG THERAPEUTICS, INC. (TGTX) has 31 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is TG THERAPEUTICS, INC.'s lead drug candidate?
TG THERAPEUTICS, INC.'s most advanced tracked candidate is allogeneic engineered gingival fibroblasts (Phase 1) for Osteoarthritis, Knee.
What is TG THERAPEUTICS, INC.'s next catalyst?
TG THERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Study to Assess the Effica" — expected July 30, 2026.
What is TG THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, TG THERAPEUTICS, INC. has approximately 114.6 months of cash runway.
What is TG THERAPEUTICS, INC.'s market capitalization?
TG THERAPEUTICS, INC.'s market capitalization is approximately $7.9B.
Get the full picture on TG THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.